Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent.

Non-drug eluting devices, such as bare-metal stents, catheters, and implantable medical devices, are widely used in procedures where drug elution is not necessary, or where a more mechanical or ...

A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...

Non-drug eluting devices, such as bare-metal stents, catheters, and implantable medical devices, are widely used in procedures where drug elution is not necessary, or where a more mechanical or ...

Boston Scientific has recently reported the results of the Optical Coherence Tomography Drug Eluting ... of this stent platform in larger groups of patients. Elixir Medical (CA, USA) reported ...

You’ll usually need to continue dual antiplatelet drug therapy for a year after a drug-eluting ... emergency medical attention any time you develop potential side effects of stent thrombosis ...

WASHINGTON--(BUSINESS WIRE)--Elixir Medical, a developer of disruptive ... to contemporary Resolute Onyx ™ zotarolimus drug-eluting stent (DES) for target lesion failure (TLF) in complex patient ...

Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior ...

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final two rounds ...

As per GlobalData’s report, India’s coronary drug eluting stent market accounts for around ... potential to enhance its role in the global medical device industry”, Chauhan added.

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral artery disease (PAD). The data, which was presented as a ...